Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)
Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%
Immunocore operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Immunocore's operating cash flow for the twelve months ending Jun 30, 2026 was -$34.96M, down 204.1% year over year. For fiscal 2025 it was -$10.71M, down 141.1% from the year before. The highest annual figure on record is $26.06M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.71M | -141.1% |
| FY2024 | Dec 31, 2024 | $26.06M | +786.4% |
| FY2023 | Dec 31, 2023 | $2.94M | – |
| FY2022 | Dec 31, 2022 | -$49.21M | – |
| FY2021 | Dec 31, 2021 | -$143.11M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.93M | -38.7% |
| Q1 FY2026 | Mar 31, 2026 | -$13.78M | -3266.7% |
| Q4 FY2025 | Dec 31, 2025 | -$32.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.46M | -121.1% |
| Q2 FY2025 | Jun 30, 2025 | $25.96M | +10.6% |
| Q1 FY2025 | Mar 31, 2025 | $435.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.95M | – |
| Q3 FY2024 | Sep 30, 2024 | $21.13M | +109.4% |
| Q2 FY2024 | Jun 30, 2024 | $23.47M | +52060.0% |
| Q1 FY2024 | Mar 31, 2024 | -$4.59M | -143.5% |
| Q4 FY2023 | Dec 31, 2023 | -$17.73M | – |
| Q3 FY2023 | Sep 30, 2023 | $10.09M | – |
| Q2 FY2023 | Jun 30, 2023 | $45.00K | – |
| Q1 FY2023 | Mar 31, 2023 | $10.54M | – |
See a number that looks wrong?